Jacob Sands, MD

Articles

Dr Sands on Updated Efficacy Findings With Tarlatamab in Previously Treated SCLC

October 10th 2024

Jacob Sands, MD, discusses updated efficacy findings with tarlatamab treatment in previously treated patients with small cell lung cancer.

Dr Sands on Consolidation Durvalumab as a Potential New SOC for LS-SCLC After Chemoradiation

September 27th 2024

Jacob Sands, MD, discusses consolidation therapy durvalumab as a new standard of care in limited-stage small cell lung cancer.

Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC

September 27th 2024

Jacob Sands, MD, presents promising early-phase trial results for obrixtamig, a novel DLL3-targeting T-cell engager, in patients with large cell neuroendocrine carcinoma of the lung (LCNEC-L), shared at ESMO Congress 2024.

Dr Sands on the Evolving Role of ADCs in SCLC Management

July 25th 2024

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Datopotamab Deruxtecan (Dato-DXd) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) – Nonsquamous (NSQ) Histology in the Phase 3 TROPION-Lung01 Trial

April 9th 2024

Jacob Sands, MD, shares updated data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan versus docetaxel in non-squamous non-small cell lung cancer recently presented at the 2024 European Lung Cancer Congress (ELCC).

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Expert Perspectives on Trop-2 Biomarker Expression in Lung Cancer and the Potential Role of Dato-DXd

April 8th 2022

In this expert interview, Jacob Sands, MD, shares key insights on unmet needs in the treatment of lung cancer, comments on the role of clinical trials investigating Trop-2-targeted therapy, and considers the potential impact of datopotamab deruxtecan (Dato-DXd) on the treatment landscape if it receives FDA approval for use in lung cancer.

Dr. Sands on the Importance of NGS Testing in Lung Cancer

February 4th 2022

Jacob Sands, MD, physician, discusses the importance of next-generation sequencing testing in lung cancer.

Dr. Sands on the FDA Approval of Lurbinectedin in Small Cell Lung Cancer

June 19th 2020

Jacob Sands, MD, discusses the FDA approval of lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.

Dr. Sands on the Rationale to Explore DS-1062 in Advanced NSCLC

June 20th 2019

Jacob Sands, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses the rationale to explore DS-1062 in advanced non–small cell lung cancer (NSCLC).